Tags

Type your tag names separated by a space and hit enter

Baricitinib set to join the Covid-19 therapeutic arsenal?
Rheumatology (Oxford). 2021 04 06; 60(4):1585-1587.R

Authors+Show Affiliations

Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.Centre for Rheumatic Disease, King's College London, London, UK.Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, , Cambridge, UK. Division of Experimental Medicine & Immunotherapeutics, School of Clinical Medicine, University of Cambridge, , Cambridge, UK.Centre for Rheumatic Disease, King's College London, London, UK.Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, , Cambridge, UK. Division of Experimental Medicine & Immunotherapeutics, School of Clinical Medicine, University of Cambridge, , Cambridge, UK.Division of Experimental Medicine & Immunotherapeutics, School of Clinical Medicine, University of Cambridge, , Cambridge, UK. Cambridge University Hospitals NHS Foundation Trust, , Cambridge, UK.Department of Medicine, University of Cambridge, Cambridge, UK.Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Pub Type(s)

Editorial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

33502499

Citation

Gudu, Tania, et al. "Baricitinib Set to Join the Covid-19 Therapeutic Arsenal?" Rheumatology (Oxford, England), vol. 60, no. 4, 2021, pp. 1585-1587.
Gudu T, Stober C, Cope AP, et al. Baricitinib set to join the Covid-19 therapeutic arsenal? Rheumatology (Oxford). 2021;60(4):1585-1587.
Gudu, T., Stober, C., Cope, A. P., Cheriyan, J., Galloway, J., Wilkinson, I. B., Kostapanos, M., Jayne, D., & Hall, F. (2021). Baricitinib set to join the Covid-19 therapeutic arsenal? Rheumatology (Oxford, England), 60(4), 1585-1587. https://doi.org/10.1093/rheumatology/keab061
Gudu T, et al. Baricitinib Set to Join the Covid-19 Therapeutic Arsenal. Rheumatology (Oxford). 2021 04 6;60(4):1585-1587. PubMed PMID: 33502499.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Baricitinib set to join the Covid-19 therapeutic arsenal? AU - Gudu,Tania, AU - Stober,Carmel, AU - Cope,Andrew P, AU - Cheriyan,Joseph, AU - Galloway,James, AU - Wilkinson,Ian B, AU - Kostapanos,Michalis, AU - Jayne,David, AU - Hall,Frances, PY - 2020/11/20/received PY - 2021/01/11/revised PY - 2021/01/15/accepted PY - 2021/1/28/pubmed PY - 2021/4/21/medline PY - 2021/1/27/entrez SP - 1585 EP - 1587 JF - Rheumatology (Oxford, England) JO - Rheumatology (Oxford) VL - 60 IS - 4 SN - 1462-0332 UR - https://www.unboundmedicine.com/medline/citation/33502499/Baricitinib_set_to_join_the_Covid_19_therapeutic_arsenal L2 - https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/keab061 DB - PRIME DP - Unbound Medicine ER -